Anidulafungin versus Fluconazole for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. METHODS: Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole. All patients could receive oral fluconazole after 10 days of intravenous therapy. The primary efficacy analysis assessed the global response (clinical and microbiologic) at the end of intravenous therapy in patients who had a positive baseline culture. Efficacy was also assessed at other time points. RESULTS: Eighty-nine percent of the 245 patients in the primary analysis had candidemia only. Candida albicans was isolated in 62% of the 245 patients. In vitro fluconazole resistance was infrequent. Most of the patients (97%) did not have neutropenia. At the end of intravenous therapy, treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (difference, 15.4 percentage points; 95% confidence interval [CI], 3.9 to 27.0). The results were similar for other efficacy end points. The statistical analyses failed to show a "center effect"; when data from the site enrolling the largest number of patients were removed, success rates at the end of intravenous therapy were 73.2% in the anidulafungin group and 61.1% in the fluconazole group (difference, 12.1 percentage points; 95% CI, -1.1 to 25.3). The frequency and types of adverse events were similar in the two groups. The rate of death from all causes was 31% in the fluconazole group and 23% in the anidulafungin group (P=0.13). CONCLUSIONS: Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (ClinicalTrials.gov number, NCT00056368 [ClinicalTrials.gov]).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [141]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
In the citing paper
“A randomized controlled trial, more robust for examining effects of treatment, found superior outcomes for patients who received an echinocandin as primary treatment for invasive candidiasis [12].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [12]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Research works printed but not linked: 4
- Graybill JR, 2001, Curr Opin Investig Drugs, 2, 468
- Espinel-Ingroff A, 2003, Rev Iberoam Micol, 20, 121
- Park S, Paderu P, Perlin DS. Amino acid polymorphisms in Fks1 from C. parapsilosis, C. metapsilosis and C. orthopsilosis strains account for intrinsic reduced susceptibility to echinocandin drugs. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
- 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(19960830)15:16<1729::aid-sim334>3.0.co;2-m
Cited by
Items 701–800 of 892
Early Recognition of Invasive Candidiasis in the ICU
Charles, P., Bruyère, R., & Dalle, F. (2012) · Springer eBooks · doi:10.1007/978-3-642-25716-2_29 · Cited by 2
Strategien bei Versagen einer antimykotischen Therapie auf Intensivstation
Arens, C., Bernhard, M., Koch, C., Heininger, A., Störzinger, D., Hoppe‐Tichy, T., Hecker, M., Grabein, B., Weigand, M. A., & Lichtenstern, C. (2015) · Der Anaesthesist · doi:10.1007/s00101-015-0072-0 · Cited by 1
Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on Candida parapsilosis
Kale-Pradhan, P. B., Wilhelm, S. M., & Johnson, L. B. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0087-9 · Cited by 1
Austrian Clinical Practice with Anidulafungin in 2008: A Multicenter Survey
Perkhofer, S., Hell, M., Gustorff, B., von Goedecke, A., Illievich, U. M., Kratzer, C., Moosbauer, W., Wimmer, P., Zerlauth, U., Nachbaur, K., et al. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.5.285 · Cited by 1
Echinocandins for Primary Therapy of Candidemia: Time for a Paradigm Shift?
Colombo, R. E., & Vázquez, J. A. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0215-9 · Cited by 2
Contreras-Hernández, I., Mould-Quevedo, J. F., Zendejas-Villanueva, J. L., Sánchez, J. A. G., Mejía‐Aranguré, J. M., & Garduño‐Espinosa, J. (2011) · PharmacoEconomics Spanish Research Articles · doi:10.1007/bf03320885 · Cited by 1
Particularidades clínicas del paciente crítico con infección fúngica invasora
Borges-Sa, M., & Aranda-Pérez, M. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.03.008 · Cited by 3
Vehreschild, M. J. G. T., & Cornely, O. A. (2015) · Der Internist · doi:10.1007/s00108-015-3704-1 · Cited by 1
Anidulafungin vs. Fluconazole for Invasive Candidiasis
Ampel, N. M. (2007) · Journal watch · doi:10.1056/id200706130000001 · Cited by 1
Wierzbowska, A., & Pluta, A. (2011) · Via Medica Journals · Cited by 3
Heizmann, P., & Heizmann, W. R. (2009) · Intensivmedizin und Notfallmedizin · doi:10.1007/s00390-008-0011-2 · Cited by 1
Keiler, S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-16 · Cited by 1
Potencial de anidulafungina en el paciente hematológico
López, L. V., & Ruíz-Camps, I. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76592-3 · Cited by 1
Fungal Infections in Cancer Patients
Granwehr, B. P., Sipsas, N. V., & Kontoyiannis, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_121 · Cited by 1
Lemmen, S. (2014) · Springer eBooks · doi:10.1007/978-3-642-54953-3_71 · Cited by 1
Traboulsi, R. S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-17 · Cited by 1
Lugo, D. J., & Steinbach, W. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00293-7 · Cited by 1
Kraft, L., Ribeiro, V. S. T., Gonçalves, G. A., Suss, P. H., & Tuon, F. F. (2023) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.07.009 · Cited by 4
Fungal Infections in the Hospitalized Patient
Odom, D. C., & Reno, H. (2015) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2015.03.005 · Cited by 2
Aguilar, C., Serris, A., Paccoud, O., Jullien, V., Alanio, A., Frange, P., Lanternier, F., & Lortholary, O. (2026) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(25)45573-2 · Cited by 1
Management of Invasive Candidiasis in the Critically Ill
Garnacho‐Montero, J., Díaz‐Martín, A., & Márquez-Vácaro, J. A. (2012) · Springer eBooks · doi:10.1007/978-3-642-25716-2_30 · Cited by 2
“The number of patients with forms of invasive disease other than candidemia who have been included in clinical trials evaluating new antifungals agents is low, ranging from 7 to 19 % [31, 32, 33], impeding sub-analysis of these patients’ data.”
BackgroundInfluentialInvasive opportunistic mycoses: Clinical trials review, 2007–2008
Groll, A. H. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-008-0073-0 · Cited by 1
“This clinical trial demonstrated the effectiveness of LAMB, 3 mg/kg/d, as fi rst-line therapy for invasive aspergillosis, with outcomes similar to the identical study design of the pivotal trial that established the fi rst-line effi cacy of voriconazole [ 2 ].”
ResultSeal, P., & Pappas, P. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-7020-4064-1.00060-9 · Cited by 2
Self-citationCandida Infections in Hematopoietic and Solid Organ Transplant Recipients
Freifeld, A. G., & Kauffman, C. A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_32 · Cited by 1
Durand, M. L. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00116-8 · Cited by 1
Freissmuth, M. (2020) · Springer eBooks · doi:10.1007/978-3-662-58304-3_59 · Cited by 1
Tejasvini, C. S., Sekhar, S., Verma, R., & Kumar, L. (2022) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2022.1516660 · Cited by 1
Antifungal Therapy in Patients with Hematological Malignancies
Herbrecht, R., & Nivoix, Y. (2010) · Springer eBooks · doi:10.1007/978-3-642-15742-4_44 · Cited by 1
“Anidulafungin has been successfully assessed in Candida infections [39, 93, 115].”
BackgroundReiss, E., Shadomy, H. J., & Lyon, G. M. (2011) · Wiley eBooks · doi:10.1002/9781118101773.ch3a · Cited by 1
Pathogens in Sepsis: Fungi, Parasites
Mechai, F., Bruneel, F., Lanternier, F., Legriel, S., Bédos, J., & Lortholary, O. (2008) · Wiley eBooks · doi:10.1002/9783527626151.ch7 · Cited by 1
Papel de anidulafungina en el paciente crítico
Borges-Sa, M., & Garnacho‐Montero, J. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76591-1 · Cited by 1
The Development of Photo-activated Antimicrobial Dyes Against Opportunistic Infections
Jalab, M. (2020) · CLOK (University of Central Lancashire) · Cited by 1
DeJarnette, C. A. (2020) · doi:10.21007/etd.cghs.2020.0518 · Cited by 2
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50018-8 · Cited by 1
Susceptibility Test Methods: Yeasts and Filamentous Fungi
Johnson, E. M., & Arendrup, M. C. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0135 · Cited by 3
Susceptibility Test Methods: Yeasts and Filamentous Fungi
Johnson, E. M., & Arendrup, M. C. (2023) · Wiley eBooks · doi:10.1002/9781683670438.mcm0135 · Cited by 1
Ruhnke, M. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50066-2 · Cited by 1
Opportunistic Infections in Pediatric Blood and Marrow Transplantation
Dvorak, C. C., & Steinbach, W. J. (2013) · Pediatric oncology · doi:10.1007/978-3-642-39920-6_6
Felder, S., Grabe, K., & Mayrhofer, T. (2010) · PharmacoEconomics German Research Articles · doi:10.1007/bf03320766
14 Therapeutic Strategies in Fungal Infections
Vehreschild, M. J. G. T., Wahlers, K., & Cornely, O. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-39432-4_14
Antibiotika, Prophylaxe und Antimykotika
Lemmen, S. (2008) · Springer eBooks · doi:10.1007/978-3-540-72296-0_62
Rangel, T., & de Jesús, R. (2011) · El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León) · Cited by 1
Non- albicans Candida Infections
Sobel, J. D., & Revankar, S. G. (2014) · ASM Press eBooks · doi:10.1128/9781555815592.ch19
Padilla, M. G., Arrabal, E. G., Verd, E. V., & Torre‐Cisneros, J. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)75427-4
Current Strategies in the Treatment of Fungal Infections in the Intensive Care Unit Setting
Goldman, M., & Sarosi, G. A. (2009) · Wiley eBooks · doi:10.1002/9780470714171.ch13
García, Y. S., & Valles, R. H. (2013) · Revista de la Sociedad Venezolana de Microbiología · Cited by 5
Indications des antifongiques systémiques, spécialité par spécialité
de Guibert, S., Gandemer, V., Belleguic, C., Revest, M., Camus, C., Caulet-Maugendre, S., Cardiet, I., Faucheux, M., Meunier, C. M., & Gangneux, J. (2010) · HAL · doi:10.1684/met.2010.0282
“Le taux de réponse globale à la fin du traitement était de 75,6 % chez les patients recevant l’anidulafungine versus 60,2 % chez ceux traités par fluconazole (p = 0,009) [84].”
BackgroundKnobloch, M. (2012) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-8150
L’anidulafungine – Une nouvelle échinocandine dans les candidoses invasives
Lortholary, O. (2007) · Réanimation · doi:10.1016/s1624-0693(07)78762-5
“[7] Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al.”
BackgroundManagement of fungal infections following allogeneic stem cell transplantation
Narimatsu, H., & Kami, M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.3.373
L’anidulafungine : état de la littérature
Saliba, F. (2010) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2010.07.002 · Cited by 1
Jones, R. N., Ross, J. E., & Sheehan, D. J. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.021
Echinocandins for candidemia: a rational choice
Menichetti, F., & Tagliaferri, E. (2013) · Reviews in Health Care · doi:10.7175/rhc.v4i2s.872
Hilbert, G. (2007) · Réanimation · doi:10.1016/s1624-0693(07)78766-2 · Cited by 2
Combination Antifungal Therapy: Is it for everyone and every mycosis?
Graybill, J. R. (2012) · Infectio · doi:10.1016/s0123-9392(12)70022-x
Candidemia e candidosi generalizzata
Eggimann, P., & Pittet, D. (2010) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(10)70266-8 · Cited by 1
Les échinocandines : mise au point
Pilmis, B., Lopes, A., Lortholary, O., & Charlier, C. (2013) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2013.02.005 · Cited by 2
Fisher, B. T., Dvorak, C. C., & Alexander, S. W. (2014) · Pediatric oncology · doi:10.1007/978-3-662-44317-0_14
Blyth, C. C., Hale, K. A., Palasanthiran, P., O'Brien, T. A., & Bennett, M. H. (2010) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.629
Nouvelles approches thérapeutiques des infections fongiques : place des nouvelles molécules
Montravers, P., Chterev, V., Augustin, P., & Etchegoyen, L. (2008) · Antibiotiques · doi:10.1016/j.antib.2007.12.003
Neoh, C. F., Kong, D. C. M., Slavin, M. A., & Chen, S. C.-A. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0085-y
“Three RCTs demonstrated the efficacy of an echinocandin to a comparator antifungal agent [108–110]”
BackgroundAnidulafungine : perspectives cliniques en 2007
Lortholary, O. (2007) · Réanimation · doi:10.1016/s1624-0693(07)78765-0
“Dans une étude de non-infériorité récemment publiée [2] dans le New England Journal of Medicine — randomisée anidulafungine versus fluconazole, multicentrique, en double aveugle, menée chez 245 patients avec une candidose invasive — l’anidulafungine s’est révélée plus efficace que le fluconazole [3].”
BackgroundInfluentialRates of Treatment Discontinuation Due to Adverse Events for Echinocandins
Müller, E. E., Wang, J., & Chang, C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00055-11
Blennow, O. (2014) · Figshare
Candidemia por Candida parapsilosis durante un tratamiento con caspofungina
Urbón, J. M. G., Galeiras, R., Fernández, D. V., & Rocha, L. Á. (2011) · Farmacia Hospitalaria · doi:10.1016/j.farma.2010.06.009
Infections fongiques invasives : un quart de siècle de progrès
Herbrecht, R., & Cordonnier, C. (2008) · Hématologie · doi:10.1684/hma.2008.0299
“Trois éléments marquants ont été le bénéfice en termes de survie dans les aspergilloses invasives grâce au voriconazole, l’extension du spectre d’action à des Candida résistant au fluconazole avec l’apparition des échinocandines et des nouveaux triazolés, et une plus grande sécurité d’emploi [3-6].”
Antifungal Susceptibility Testing and Therapy
Cuenca‐Estrella, M., & Rodríguez-Tudela, J. L. (2009) · Springer eBooks · doi:10.1007/978-3-642-03150-2_14
Fungal Infections in Stem Cell Transplant Recipients
Neofytos, D., & Marr, K. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_29
Tratamiento profiláctico antifúngico en pacientes críticos y en alto riesgo
Solís-Ayala, E., González, A. D. C. G., Hernández, B. V., Weber, F. L. R., & Greene, E. J. D. (2014) · Medicina Interna de México · Cited by 1
Anidulafungine : une nouvelle option thérapeutique dans les candidoses systémiques
Lanternier, F., & Lortholary, O. (2010) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.12.002
Antifungals for Candidosis Treatment
Grégio, A. M. T., Veiga, F. F., Rinaldi, M. G., & Bettega, P. V. C. (2015) · Springer eBooks · doi:10.1007/978-3-662-47194-4_4
Infections fongiques sévères en réanimation
Lerolle, N., Parize, P., & Lortholary, O. (2013) · Références en réanimation · doi:10.1007/978-2-8178-0389-0_17
Canbay, A. E., & Glöckner, A. (2013) · Wiener klinisches Magazin · doi:10.1007/s00740-015-0060-7
“Grundpfeiler der Diagnostik einer Candidämie/invasiven Candidiasis ist die Blutkultur, die durch serologische Untersuchungen, wie dem Nachweis von β-D-Glucan oder Mannan/anti-Mannan, ergänzt wird.”
BackgroundInfluentialInvasive Candidiasis in Management of Infections in Cancer Patients
Bassetti, M., Mikulska, M., Gea‐Banacloche, J., & Viscoli, C. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-644-3_24
“Systemic antifungal agents with activity against Candida include amphotericin B (AmB, both deoxycholate (AmB-d) [34, 62] and lipid formulations (L-AmB) [33], triazoles (fluconazole [63], itraconazole [64], voriconazole [65, 66], and posaconazole [67]), and echinocandins (micafungin, caspofungin, and anidulafungin) are…”
BackgroundInfluentialКолбин, А. С., Koroleva, O. A., & Климко, Н. Н. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.22625/2072-6732-2010-2-1-42-50
“, 2007 [19] Анидулафунгин 127 75,6 22,8 24,4”
A Multicenter, Randomized Trial of Prophylactic Fluconazole in Preterm Neonates
Stockman, J. A. (2009) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)79119-x
Épidémiologie des infections invasives à candida au Centre Hospitalier Universitaire d'Amiens
Garnier, J. (2015) · HAL
Léčba invazivní kandidózy - doporučení odborných společností
Haber, J., Ráčil, Z., Mayer, J., Mallátová, N., Kouba, M., Sedláček, P., Faber, E., Herold, I., Múdrý, P., Drgoňa, Ľ., et al. (2008) · Vnitřní lékařství
THÈSE POUR LE DIPLÔME D'ÉTAT DE
Médecine, D. E. (2007)
Servicio de Lactantes y Niños Pequeños, Hospital Universitario 12 de Octubre, Madrid, España
Infante-López, M. E., & Rojo‐Conejo, P. (2009)
Bellis, P. D. (2009) · Drugs · doi:10.2165/11315580-000000000-00000
“Drug-interaction studies involving ciclosporin, tacrolimus, rifampicin, amphotericin B and voriconazole have been carried out and have revealed that anidulafungin does not influence the pharmacological properties of these drugs.([23,24]) Anidulafungin appears to have a favourable safety and tolerability profile,([24-2…”
BackgroundCandida infection in the intensive care unit
Moore, L. S. P., & Schelenz, S. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199665754.003.0010
Echinocandins – Caspofungin, Anidulafungin and Micafungin
Lewis, R. E., & Kontoyiannis, D. P. (2010) · CRC Press eBooks · doi:10.1201/b13787-145
Mechanisms of Action of Antifungal Agents
Flowers, S. A., & Rogers, P. (2015) · CRC Press eBooks · doi:10.1201/b17871-14
Brooks, Y. P., Brooks, I. P., & Pubillones, P. O. P. (2011) · DOAJ (DOAJ: Directory of Open Access Journals)
Antifungal Management in Risk Groups: Transplant Recipients
Costa, S. F., & Alexander, B. D. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-25
Treating Common Fungal Infections in Children
Campbell, A. J., McLeod, C., & Blyth, C. C. (2016) · Current Pediatrics Reports · doi:10.1007/s40124-016-0110-7
ERG11-Mediated Azole Resistance in Candida albicans
Flowers, S. A. (2013) · doi:10.21007/etd.cghs.2013.0096
“Echinocandins are used for treatment of invasive candidiasis based on results of three defining clinical trials in which caspofungin, micafungin and anidulafungin were shown non-inferior to amphotericin B, liposomal amphotericin B and fluconazole, respectively (92, 121, 154).”
Spectrum of Activity, Pharmacology, and Clinical Indications
Nett, J. E., & Andes, D. R. (2015)
Update: invasive Pilzinfektionen Diagnose und Therapie in der operativen Intensivmedizin
Anaesthesiologie, K. F., Heidelberg, U., & Briegel, J. (2010)
Boutoille, D., Tattevin, P., Weinbreck, P., Ansart, S., Hutin, P., Leautez-Nainville, S., Raffi, F., Hôtel-Dieu, C., & de Limoges, C. (2009)
The Role of Candida in Abdominal Sepsis
Montravers, P., Snauwaert, A., Genève, C., & Rehouma, M. B. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_19
A study on rapid diagnosis (by PCR) and cost-effective treatment of pulmonary mycosis
Kumar, S., Shaifali, I., & Chandra, S. (2018) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20182041
“Table 1: Probability of clinical success and mortality rate.(15)”
BackgroundMethodInfluentialAli, S. M. (2018) · Research in Pediatrics & Neonatology · doi:10.31031/rpn.2018.02.000526
Antifungal Dosing Considerations for Term and Preterm Infants
Lestner, J. M., & Hope, W. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54391-0.00015-1
Rüping, M. J. G. T., Vehreschild, J. J., Ewig, S., & Cornely, O. A. (2009) · Wiley eBooks · doi:10.1002/9780470714171.ch6
Metadata
- Authors
- Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., & Walsh, T. J.
- Affiliations
- Cooper University Hospital (US)
- Hamilton Health Sciences (CA)
- University of Alabama at Birmingham (US)
- University of Mississippi (US)
- University of Miami (US)
- University Health Network (CA)
- University of Rochester (US)
- Vifor Pharma (Germany) (DE)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2472-2482
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126319933
- Cited by
- 894
- References
- 27
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 33 · 2022: 23 · 2021: 37 · 2020: 47 · 2019: 34 · 2018: 40 · 2017: 29 · 2016: 34 · 2015: 44 · 2014: 46 · 2013: 55 · 2012: 52
- FWCI
- 58.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Eli Lilly and Company
- Pfizer
- Viropharma
- Astellas Pharma
- Basilea Pharmaceutica
- Duke Clinical Research Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- anidulafungin, fluconazole, invasive candidiasis, echinocandins, candidemia, Candida albicans, non-inferiority, antifungal therapy, mortality, fluconazole resistance
- MeSH terms
- Anidulafungin, Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Candidiasis, Double-Blind Method, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Peptides, Cyclic, Fluconazole, Fungemia, Treatment Outcome, Kaplan-Meier Estimate, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.